ADVANCED HR+/HER2- BREAST CANCER
Clinical trials for ADVANCED HR+/HER2- BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED HR+/HER2- BREAST CANCER trials appear
Sign up with your email to follow new studies for ADVANCED HR+/HER2- BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for Hard-to-Treat breast cancer
Disease control Recruiting nowThis study tests a new drug called GVV858, alone or with hormone therapy, in people with advanced hormone receptor-positive, HER2-negative breast cancer and other solid tumors. The goal is to find the safest dose and see how well it works. About 205 adults whose cancer has progre…
Matched conditions: ADVANCED HR+/HER2- BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug IEV407 takes on advanced breast cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called IEV407, alone or with hormone therapy, in people with advanced HR+/HER2- breast cancer that has stopped responding to standard treatments. The main goals are to check safety and find the right dose. About 194 participants will take p…
Matched conditions: ADVANCED HR+/HER2- BREAST CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New combo therapy aims to control advanced breast cancer
Disease control Recruiting nowThis study tests a new drug called ECI830, alone or with other cancer drugs (ribociclib and fulvestrant), in people with advanced hormone receptor-positive, HER2-negative breast cancer or certain solid tumors. The goal is to find safe doses and see if the combination can slow can…
Matched conditions: ADVANCED HR+/HER2- BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC